Novadoz Pharmaceuticals secured FDA approval June 3, 2026, for oral Tofacitinib Citrate tablets, positioning the firm to capitalize on a significant rheumatoid arthritis market. This ANDA approval sets the stage for increased generic competition, threatening incumbent market share through cost reductions and price pressure.